Trevi Therapeutics (TRVI) is pleased to announce today positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF. The primary endpoint in the CORAL trial was achieved, demonstrating statistically significant reductions in 24-hour cough frequency across all dose groups at Week 6. The 108 mg BID, 54 mg BID and 27 mg BID dose groups achieved reductions from Baseline of 60.2%, 53.4%, and 47.9%, respectively, compared to a placebo reduction from Baseline of 16.9%1. Statistically significant improvements were observed across secondary endpoints at Week 6 in the 108 mg BID and 54 mg BID dose groups.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Trevi Therapeutics’ Strong Market Potential and Revenue Opportunities Highlighted in Buy Rating
- Trevi Therapeutics initiated with a Buy at H.C. Wainwright
- Promising Phase 2a Results for Trevi Therapeutics’ Haduvio Highlight Potential in RCC and IPF-Cough Markets
- Trevi Therapeutics: Promising Developments and Positive Outlook for Haduvio Program
- Trevi Therapeutics provides additional analysis of Haduvio in chronic cough